Peritoneal Cancer
Conditions
Keywords
peritoneal surface malignancies, cytoreductive surgery, hyperthermic intraperitoneal chemotherapy
Brief summary
The purpose of this study is to assess the dynamics of inflammatory parameters in presence or absence of infectious complications after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.
Detailed description
Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy is the treatment of choice in patients with primary or secondary peritoneal surface malignancies. However the survival benefit is achieved at the cost of increased morbidity and mortality due to an extensive surgery and intraoperative chemo-therapy. Among complications infectious complications are the most common. The early diagnosis of a potential fatal infection is therefore crucial to ensure a good outcome in patients.
Interventions
PROCEDURECRS and HIPEC
During CRS, all visible peritoneal tumors are removed. Consequently micrometastasis are removed with hyperthermic intraperitoneal chemotherapy
Sponsors
University of Zurich
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Consecutive adult patients (more than 18 years) subjected to CRS and HIPEC due to peritoneal malignancy. * Written informed consent by the participant after information about the research project
Exclusion criteria
* No primary or secondary peritoneal surface malignancy * No CRS and HIPEC * Pregnancy * Younger than 18 years
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| C reactive protein (CRP) mg/l, receiver operating characteristic (ROC) | 30 days |
Countries
Switzerland
Contacts
Primary ContactKuno Lehmann, MD, PhD
Backup ContactDilmurodjon Eshmuminov, MD
Outcome results
None listed